Obvious that these authors listed ChatGPT to get attention. The papers themselves are very short. The medxriv preprint [1] should be a blogpost. The paper in Oncoscience is nonsense [2]. It was submitted on Dec 14th and accepted on Dec 15th 2022, apparently contravening the journal’s stated peer review policy (find me an article anywhere that gets peer reviewed in under 24 hours). The journal presumably realised the clickbait value and rushed it through.
Suffice to say, the authors’ cheap strategy has worked. The medrxiv preprint has an impressive view and retweet count. Expect a flood of ChatGPT authored papers.
[1] https://www.medrxiv.org/content/10.1101/2022.12.19.22283643v...